White House credits GLP-1 price cuts and TrumpRx for record drop in drug prices

The White House said on Aug. 17 that prescription drug prices have fallen more than in any year since 1963, crediting its most-favored-nation pricing campaign and the TrumpRx discount site ^[1]. The release puts cumulative patient savings from TrumpRx at $700 million since the platform opened in February, and says GLP-1 medicines that used to run above $1,000 a month now start as low as $149 ^[1].

Other figures in the release: prescription drug prices are 3.9% lower than when the administration began, with no monthly increases so far in 2026; nonprescription drugs are down 2.4% over the same stretch; and medical care commodities, equipment and supplies included, are down 2.7% year over year ^[1]. According to the release, the Department of Veterans Affairs has booked more than $10 billion in pharmaceutical savings during the current fiscal year, and 17 manufacturers covering roughly 86% of the branded drug market have agreed to match U.S. prices to the lowest ones paid in comparable developed countries ^[1].

Federal inflation data point the same direction, with different numbers. Axios, citing the Consumer Price Index, reports a 0.8% decline in July and a 3.1% drop over 12 months, described as the steepest annual fall in over six decades ^[2]. Hospital and physician services, by contrast, keep getting more expensive ^[2]. The figures measure different windows: 3.9% from the start of the administration ^[1], 3.1% over the past year ^[2].

What is driving the decline is contested. Axios reports that TrumpRx probably accounts for only a slice of it ^[2]. Deals between Eli Lilly and Novo Nordisk and the administration trimmed cash prices for leading GLP-1 drugs and widened Medicare access, and negotiated Medicare prices for 10 of the program's costliest drugs took effect in January at discounts reaching 79% below list ^[2]. Generic competition and rivalry among GLP-1 makers are also pushing cash prices down ^[2].

Geoffrey Joyce, a health economist at the University of Southern California, said TrumpRx largely makes discounts that already existed easier to find, and that the Inflation Reduction Act deserves much of the policy credit ^[2]. White House spokesperson Kush Desai rejected that framing, calling it "idiotic and unfounded" and arguing the negotiated prices delivered little beyond what insurers had already won; he pointed instead to the most-favored-nation agreements and TrumpRx ^[2].

The release does not say which GLP-1 products carry the $149 starting price, or whether it applies to insured purchases as well as cash pay ^[1]. TrumpRx connects patients with discounted cash prices for selected drugs ^[2].

Why it matters for patients

Average price changes are a rough guide to what any one person pays. The prescription drug CPI tracks what pharmacies are paid by patients and insurers, Medicare included, and does not capture manufacturer rebates paid after the transaction, the Bureau of Labor Statistics told Axios ^[2]. Falling averages can therefore sit alongside an unchanged copay.

Joyce said patients judge prices by what they hand over at the counter. "People don't care about what the true cost of the drug is," he said. "They just say, 'What's my copay?' or 'What's my cost sharing at the pharmacy counter?'" ^[2]

Cost worry is at its highest level KFF has recorded since it began asking in 2018: six in 10 Americans this spring, with four in 10 saying cost had kept them from taking medication as prescribed in the past year ^[2].

What happens next

The White House says the full most-favored-nation framework is projected to produce hundreds of billions of dollars in additional long-term savings, though the release gives no timeline for when those would appear ^[1]. Medicare's negotiated prices for the first 10 selected drugs are already in effect as of January ^[2].